CDC7 and cancer: TQB3824 is a small-molecule CDC7 inhibitor that demonstrated antitumor efficacy in solid tumor models with CDC7 overexpression; it is being investigated in a phase I trial enrolling patients with advanced cancer (NCT05028218; ref. 19).